Detail

CHEPLAPHARM acquires global rights to Questran® from Bristol-Myers Squibb

CHEPLAPHARM Arzneimittel GmbH continues with its diversification strategy.

 

CHEPLAPHARM Arzneimittel GmbH continues with its diversification strategy.

QUESTRAN® is a prescription drug that is registered in 20 countries worldwide - France, United Kingdom, Italy, Brazil and Germany being the top 5 countries.
Containing the active ingredient Cholestyramine, QUESTRAN® is mainly used to reduce the risk of heart attack and stroke in patients with primary hypercholesterolemia.

“With the acquisition and integration of QUESTRAN® into our product portfolio, we do not only continue the very successful cooperation with Bristol-Myers Squibb, but we also reinforce our International Footprint in the respective territories”, said CEO Sebastian F. Braun.

After years of successful development of the global partner network, CHEPLAPHARM further continues its long-term success story by scaling the business model.

Press Office:
CHEPLAPHARM Arzneimittel GmbH | Ziegelhof 24 | 17489 Greifswald | presse(at)cheplapharm.com

Back